S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Bear Market Funds to Watch This Year
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Bear Market Funds to Watch This Year
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Bear Market Funds to Watch This Year
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Bear Market Funds to Watch This Year
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Geron Co. stock logo
GERN
Geron
$3.73
+1.4%
$2.71
$1.64
$4.05
$2.01B0.6210.25 million shs9.74 million shs
Kamada Ltd. stock logo
KMDA
Kamada
$5.10
+0.4%
$5.78
$4.08
$6.53
$291.97M1.0421,148 shs6,510 shs
Lannett Company, Inc. stock logo
LCI
Lannett
$1.54
$0.64
$3.72
$7.38M0.9592,067 shs280,600 shs
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
$0.00
$0.07
$4.08
$3.50M2.57848,888 shsN/A
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
$1.30
+2.4%
$1.30
$0.25
$1.40
$70.12M1.32515,333 shs862,700 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Geron Co. stock logo
GERN
Geron
+1.36%-1.06%+14.42%+97.35%+49.80%
Kamada Ltd. stock logo
KMDA
Kamada
+0.39%-1.92%-11.15%-13.12%+9.68%
Lannett Company, Inc. stock logo
LCI
Lannett
0.00%0.00%0.00%0.00%0.00%
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
0.00%0.00%0.00%0.00%+25.00%
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
0.00%0.00%0.00%0.00%+223.79%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Geron Co. stock logo
GERN
Geron
3.2026 of 5 stars
3.53.00.01.31.41.70.6
Kamada Ltd. stock logo
KMDA
Kamada
4.128 of 5 stars
3.55.00.00.02.61.73.1
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/AN/AN/AN/AN/A
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Geron Co. stock logo
GERN
Geron
3.00
Buy$5.3342.98% Upside
Kamada Ltd. stock logo
KMDA
Kamada
3.00
Buy$11.00115.69% Upside
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/A
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/AN/AN/AN/A
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
2.00
Hold$1.11-14.62% Downside

Current Analyst Ratings

Latest ZYNE, LCI, PHAS, GERN, and KMDA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/11/2024
Geron Co. stock logo
GERN
Geron
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
4/10/2024
Geron Co. stock logo
GERN
Geron
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$6.00
3/15/2024
Geron Co. stock logo
GERN
Geron
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$6.00
3/15/2024
Geron Co. stock logo
GERN
Geron
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$4.00 ➝ $5.00
3/15/2024
Geron Co. stock logo
GERN
Geron
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$4.00 ➝ $5.00
3/7/2024
Kamada Ltd. stock logo
KMDA
Kamada
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00
2/28/2024
Geron Co. stock logo
GERN
Geron
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Geron Co. stock logo
GERN
Geron
$240K8,499.27N/AN/A$0.46 per share8.11
Kamada Ltd. stock logo
KMDA
Kamada
$142.52M2.06$0.43 per share11.91$4.25 per share1.20
Lannett Company, Inc. stock logo
LCI
Lannett
$340.58M0.00N/AN/A($23.34) per share0.00
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
$818K0.00N/AN/A($1.93) per share0.00
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
N/AN/AN/AN/A$1.01 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Geron Co. stock logo
GERN
Geron
-$184.13M-$0.33N/AN/AN/A-77,691.14%-63.33%-44.71%5/9/2024 (Estimated)
Kamada Ltd. stock logo
KMDA
Kamada
$8.28M$0.1534.0012.44N/A5.81%5.66%3.57%5/22/2024 (Estimated)
Lannett Company, Inc. stock logo
LCI
Lannett
-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/A
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/A
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
-$35.04M-$0.80N/AN/AN/AN/A-90.03%-72.62%N/A

Latest ZYNE, LCI, PHAS, GERN, and KMDA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/6/2024Q4 2023
Kamada Ltd. stock logo
KMDA
Kamada
$0.05$0.09+$0.04$0.09$37.71 million$36.43 million
2/28/2024Q4 23
Geron Co. stock logo
GERN
Geron
-$0.10-$0.09+$0.01-$0.09$0.06 million$0.02 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Geron Co. stock logo
GERN
Geron
N/AN/AN/AN/AN/A
Kamada Ltd. stock logo
KMDA
Kamada
N/AN/AN/AN/AN/A
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/AN/A
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/AN/AN/AN/AN/A
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Geron Co. stock logo
GERN
Geron
0.14
3.16
3.16
Kamada Ltd. stock logo
KMDA
Kamada
N/A
3.43
1.64
Lannett Company, Inc. stock logo
LCI
Lannett
N/A
2.23
1.39
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/A
0.47
0.47
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
N/A
3.43
3.43

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Geron Co. stock logo
GERN
Geron
73.71%
Kamada Ltd. stock logo
KMDA
Kamada
20.38%
Lannett Company, Inc. stock logo
LCI
Lannett
40.28%
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
49.02%
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
11.23%

Insider Ownership

CompanyInsider Ownership
Geron Co. stock logo
GERN
Geron
3.10%
Kamada Ltd. stock logo
KMDA
Kamada
36.10%
Lannett Company, Inc. stock logo
LCI
Lannett
13.12%
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
9.90%
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
13.04%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Geron Co. stock logo
GERN
Geron
141546.87 million529.92 millionOptionable
Kamada Ltd. stock logo
KMDA
Kamada
37857.47 million36.73 millionOptionable
Lannett Company, Inc. stock logo
LCI
Lannett
81010.77 million9.35 millionOptionable
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
6049.86 million44.92 millionNot Optionable
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
2553.94 million46.91 millionOptionable

ZYNE, LCI, PHAS, GERN, and KMDA Headlines

SourceHeadline
Harmony Biosciences Reports Strong Third Quarter 2023 Financial ResultsHarmony Biosciences Reports Strong Third Quarter 2023 Financial Results
finance.yahoo.com - October 31 at 7:57 AM
Why Shares of Harmony Bioscience Are Falling on FridayWhy Shares of Harmony Bioscience Are Falling on Friday
fool.com - October 13 at 12:59 PM
New Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder TherapiesNew Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapies
markets.businessinsider.com - October 11 at 9:47 AM
HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINEHARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE
finance.yahoo.com - October 11 at 9:47 AM
H.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE)H.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE)
knoxdaily.com - October 10 at 1:59 PM
Analysts: ZYNE stock price target of $1.25 in 12 monthsAnalysts: ZYNE stock price target of $1.25 in 12 months
knoxdaily.com - October 5 at 6:47 PM
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and InstructionsImportant Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions
finance.yahoo.com - October 4 at 7:33 PM
Examining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE)Examining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE)
knoxdaily.com - October 2 at 3:14 PM
20 Countries With Highest Rate of Epilepsy20 Countries With Highest Rate of Epilepsy
finance.yahoo.com - September 29 at 6:24 PM
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
finance.yahoo.com - September 29 at 1:23 PM
Harmony Biosciences extends deadline for Zynerba shareholders on up to $200M dealHarmony Biosciences extends deadline for Zynerba shareholders on up to $200M deal
bizjournals.com - September 27 at 2:42 PM
Zynerba Pharmaceuticals Inc [ZYNE] Investment Appeal on the RiseZynerba Pharmaceuticals Inc [ZYNE] Investment Appeal on the Rise
knoxdaily.com - September 25 at 8:15 PM
Zynerba Pharmaceuticals Inc. (ZYNE) rating reiterates by H.C. WainwrightZynerba Pharmaceuticals Inc. (ZYNE) rating reiterates by H.C. Wainwright
knoxdaily.com - September 20 at 12:12 PM
Negative sentiment towards ZYNE reflected in surge in short interestNegative sentiment towards ZYNE reflected in surge in short interest
knoxdaily.com - September 15 at 8:27 PM
Insider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals IncInsider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals Inc
finance.yahoo.com - September 14 at 11:23 PM
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research SymposiumZynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium
finance.yahoo.com - September 14 at 6:23 PM
Zynerba Pharmaceuticals Hit With Shareholder Suit in Pa. Over Allegedly Inadequate Proxy StatementZynerba Pharmaceuticals Hit With Shareholder Suit in Pa. Over Allegedly Inadequate Proxy Statement
law.com - September 11 at 4:04 PM
Positive sentiment towards ZYNE reflected in decline in short interestPositive sentiment towards ZYNE reflected in decline in short interest
knoxdaily.com - September 8 at 5:19 AM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, ZYNE, KLRSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, ZYNE, KLR
bakersfield.com - August 31 at 5:00 PM
HC Wainwright & Co. Downgrades Zynerba Pharmaceuticals (ZYNE)HC Wainwright & Co. Downgrades Zynerba Pharmaceuticals (ZYNE)
msn.com - August 16 at 4:20 AM
Harmony Makes Rare Disease Play with Potential $200M Zynerba BuyoutHarmony Makes Rare Disease Play with Potential $200M Zynerba Buyout
biospace.com - August 15 at 6:19 PM
Zynerba Pharma (NASDAQ: ZYNE) up 300% - The contingents are worth how much?Zynerba Pharma (NASDAQ: ZYNE) up 300% - The contingents are worth how much?
dhakatribune.com - August 15 at 6:19 PM
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?
finance.yahoo.com - August 15 at 6:19 PM
Zynerba Pharmaceuticals Shares Soar on Harmony Biosciences Deal >ZYNEZynerba Pharmaceuticals Shares Soar on Harmony Biosciences Deal >ZYNE
marketwatch.com - August 14 at 9:48 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Geron logo

Geron

NASDAQ:GERN
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Kamada logo

Kamada

NASDAQ:KMDA
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Lannett logo

Lannett

NYSE:LCI
Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.
PhaseBio Pharmaceuticals logo

PhaseBio Pharmaceuticals

NASDAQ:PHAS
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.
Zynerba Pharmaceuticals logo

Zynerba Pharmaceuticals

NASDAQ:ZYNE
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.